Capital International Investors Has $571.93 Million Holdings in Novo Nordisk A/S $NVO

Key Points

• Capital International Investors cut its Novo Nordisk stake by 36.7% in the fourth quarter, selling 6.5 million shares and ending with 11.2 million shares valued at about $571.9 million.
• Analysts remain cautious but broadly constructive: Novo has a consensus rating of Hold, though recent moves included Sanford C. Bernstein starting coverage with an Outperform rating and Wall Street Zen upgrading the stock to Buy.
• Investor focus remains on Novo’s obesity-drug growth story, with forecasts for the GLP-1 market rising to $150 billion by 2030 and new trial work, international expansion, and upcoming conference data potentially driving sentiment.

Capital International Investors lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 36.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,211,106 shares of the company's stock after selling 6,502,318 shares during the period. Capital International Investors owned about 0.25% of Novo Nordisk A/S worth $571,934,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $25,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $28,000. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Finally, Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: TD Cowen raised its 2030 GLP-1 sales forecast to $150 billion and expects Novo Nordisk to remain one of the two dominant leaders alongside Eli Lilly, implying continued long-term demand for obesity and diabetes therapies. GLP-1 Sales Forecast Jumps To $150 Billion By 2030
• Positive Sentiment: Novo Nordisk is expanding internationally as only 1%–2% of global patients currently use obesity drugs, suggesting a large untapped market if pricing and access improve over time. Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
• Positive Sentiment: Novo Nordisk announced a clinical supply agreement with Veru for a Phase 2b obesity trial testing Wegovy in combination with enobosarm, giving the company another potential path to extend its obesity franchise. Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
• Neutral Sentiment: Investor attention is elevated ahead of Novo Nordisk’s ADA conference data releases and June 7 R&D event, which could create volatility depending on pipeline updates and clinical readouts. Novo Nordisk gains as investors position for ADA data and June 7 R&D event
• Neutral Sentiment: Novo Nordisk is also getting broad market attention as a “trending stock,” but that reflects heightened investor interest rather than a clearly stock-moving fundamental update. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Analyst Ratings Changes

A number of brokerages have recently weighed in on NVO. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They set an "outperform" rating and a $175.00 price target for the company. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a "hold" rating in a research note on Tuesday, February 24th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research note on Thursday, February 12th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $42.93 on Monday. The company has a market cap of $191.66 billion, a price-to-earnings ratio of 10.08, a PEG ratio of 3.83 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a 50 day simple moving average of $41.62 and a 200 day simple moving average of $46.17. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Research analysts predict that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.